July 22, 2025
Now available OSENVELT®
OSENVELT® (denosumab-bmwo) is biosimilar to XGEVA® (denosumab). OSENVELT is a RANK ligand (RANKL) inhibitor indicated for:
- Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors.
- Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.
- Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy.